ATE501732T1 - Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen - Google Patents

Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen

Info

Publication number
ATE501732T1
ATE501732T1 AT03020587T AT03020587T ATE501732T1 AT E501732 T1 ATE501732 T1 AT E501732T1 AT 03020587 T AT03020587 T AT 03020587T AT 03020587 T AT03020587 T AT 03020587T AT E501732 T1 ATE501732 T1 AT E501732T1
Authority
AT
Austria
Prior art keywords
eyes
treatment
composition containing
antibiotic composition
containing moxifloxacin
Prior art date
Application number
AT03020587T
Other languages
German (de)
English (en)
Inventor
Gerald Cagle
Robert L Abshire
David W Stromann
John M Yanni
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE501732(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ATE501732T1 publication Critical patent/ATE501732T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03020587T 1998-09-30 1999-09-29 Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen ATE501732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10250498P 1998-09-30 1998-09-30
US10250698P 1998-09-30 1998-09-30

Publications (1)

Publication Number Publication Date
ATE501732T1 true ATE501732T1 (de) 2011-04-15

Family

ID=26799441

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03020587T ATE501732T1 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen
AT99956504T ATE254458T1 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzungen zur behandlung des auges

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99956504T ATE254458T1 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzungen zur behandlung des auges

Country Status (18)

Country Link
EP (5) EP2301541B1 (enExample)
JP (5) JP2002525317A (enExample)
KR (1) KR101463243B1 (enExample)
CN (2) CN1184968C (enExample)
AR (2) AR020661A1 (enExample)
AT (2) ATE501732T1 (enExample)
AU (1) AU762827B2 (enExample)
BR (1) BRPI9914151B1 (enExample)
CA (3) CA2342211C (enExample)
CY (3) CY1111404T1 (enExample)
DE (2) DE69943287D1 (enExample)
DK (5) DK2796138T3 (enExample)
ES (4) ES2519190T3 (enExample)
HK (1) HK1038691B (enExample)
PT (5) PT1384478E (enExample)
TR (2) TR200100883T2 (enExample)
TW (1) TWI222361B (enExample)
WO (1) WO2000018386A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
DE19937115A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE60006262T2 (de) 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
AU2001261748A1 (en) * 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose
CA2412575C (en) 2000-07-26 2009-12-29 Onkar N. Singh Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
AU2002214308A1 (en) * 2000-11-16 2002-05-27 Wakamoto Pharmaceutical Co., Ltd. Antibacterial gel eye drops
WO2002049633A2 (en) 2000-12-20 2002-06-27 Alcon, Inc. Use of amidoamines to treat or prevent acanthamoeba and fungal infections
WO2002049627A2 (en) * 2000-12-20 2002-06-27 Alcon, Inc. Antifungal compositions containing an antibiotic and one or more amidoamines
US20030139382A1 (en) 2001-09-21 2003-07-24 Alcon, Inc. Method of treating middle ear infections
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
PL1666477T3 (pl) 2003-09-10 2013-11-29 Kyorin Seiyaku Kk Pochodna kwasu 7-(4-podstawionego-3-cyklopropyloaminometylo-1- pirolidynylo)chinolonokarboksylowego
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
US20080124385A1 (en) * 2004-09-03 2008-05-29 Piedmont Pharmaceuticals,Llc. Methods for Transmembrane Treatment and Prevention of Otitis Media
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
EP1824499A2 (en) * 2004-12-10 2007-08-29 Alcon Inc. Compositions for treatment of ear infections
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
TWI544934B (zh) 2008-06-09 2016-08-11 愛爾康研究有限公司 含有氟喹諾酮抗生素藥物之經改良藥學組成物
JP5784012B2 (ja) * 2009-07-02 2015-09-24 アルコン リサーチ， リミテッド 眼、耳または鼻の感染症を処置するためのフィナフロキサシンを含む組成物および方法
LT2521547T (lt) * 2010-01-07 2017-12-11 Regents Of The University Of Minnesota Moksifloksacino vartojimo į ausį būdai ir kompozicijos
WO2013085769A1 (en) 2011-12-06 2013-06-13 Alcon Research, Ltd. Cellulosic gel composition with improved viscosity stability
RU2472507C1 (ru) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Водный состав на основе моксифлоксацина для парентерального введения
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
CN104224802B (zh) * 2014-09-19 2017-12-12 南京优科生物医药研究有限公司 一种盐酸莫西沙星滴耳剂及其制备方法
RU2595837C2 (ru) * 2014-09-29 2016-08-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазных капель
EP3369422A4 (en) * 2015-10-29 2018-12-05 Teika Pharmaceutical Co., Ltd. External preparation
US12042500B2 (en) * 2018-04-03 2024-07-23 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica
JP2023530254A (ja) * 2020-06-10 2023-07-14 オキュラー サイエンス，インク． 手術後の眼科的ケアのための組成物および方法
CN116270662A (zh) * 2021-12-03 2023-06-23 苏州欧康维视生物科技有限公司 盐酸莫西沙星地塞米松磷酸钠滴眼液
KR102656260B1 (ko) 2022-10-14 2024-04-09 주식회사태준제약 목시플록사신을 포함하는 안과용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
AU4201189A (en) 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
JPH03109236A (ja) * 1989-09-22 1991-05-09 Hoya Corp 半導体超微粒子分散ガラスの製造方法
TW209865B (enExample) * 1992-01-10 1993-07-21 Bayer Ag
DE69333850T3 (de) 1992-05-06 2011-03-17 Alcon Laboratories, Inc., Fort Worth Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
DE4424369A1 (de) * 1994-07-11 1996-01-18 Bayer Ag Pyrido[3,2,1.i,j][3,1]benzoxazinderivate
JPH0892241A (ja) * 1994-09-22 1996-04-09 Ss Pharmaceut Co Ltd ５−ヒドラジノキノロンカルボン酸誘導体及びこれを有効成分とする抗菌剤
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
WO1996039146A1 (en) * 1995-06-06 1996-12-12 Bayer Corporation Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions
JP3290914B2 (ja) * 1997-03-17 2002-06-10 参天製薬株式会社 眼組織におけるキノロン系抗菌剤の定量装置
BR9812553B1 (pt) * 1997-09-25 2010-06-01 formulação medicamentosa em pélete de difusão controlada e em um sistema matriz.
WO2000016736A1 (en) 1998-09-23 2000-03-30 Unilever N.V. Oral care compositions
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
KR20010107754A (ko) * 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법

Also Published As

Publication number Publication date
DK2269602T3 (en) 2014-12-15
TWI222361B (en) 2004-10-21
JP2013018799A (ja) 2013-01-31
EP2796138A1 (en) 2014-10-29
EP2269602A1 (en) 2011-01-05
EP2796138B1 (en) 2016-08-17
BRPI9914151B1 (pt) 2017-10-03
CN1650863A (zh) 2005-08-10
DK2301541T3 (da) 2014-09-01
EP1117401B1 (en) 2003-11-19
ES2519190T3 (es) 2014-11-06
EP1384478A1 (en) 2004-01-28
CA2342211A1 (en) 2000-04-06
AR081393A2 (es) 2012-08-29
TR200100883T2 (tr) 2001-10-22
DK2796138T3 (en) 2016-12-05
JP2009007375A (ja) 2009-01-15
CN100374114C (zh) 2008-03-12
BR9914151A (pt) 2001-06-26
KR101463243B1 (ko) 2014-12-17
CY1115916T1 (el) 2017-01-25
DK1117401T3 (da) 2004-02-23
ES2526521T3 (es) 2015-01-13
TR200704370T2 (tr) 2007-11-21
WO2000018386A2 (en) 2000-04-06
EP1384478B1 (en) 2011-03-16
ATE254458T1 (de) 2003-12-15
PT2269602E (pt) 2014-12-29
DK1384478T3 (da) 2011-05-23
AU1310100A (en) 2000-04-17
CA2342211C (en) 2009-05-26
EP2269602B1 (en) 2014-11-19
HK1150769A1 (en) 2012-01-13
DE69912972T2 (de) 2004-04-22
JP2002525317A (ja) 2002-08-13
CA2659064A1 (en) 2000-04-06
EP2301541B1 (en) 2014-08-20
CY1115759T1 (el) 2017-01-25
EP1117401A2 (en) 2001-07-25
CN1320035A (zh) 2001-10-31
JP5563041B2 (ja) 2014-07-30
JP2012067141A (ja) 2012-04-05
DE69943287D1 (de) 2011-04-28
PT2796138T (pt) 2016-09-22
CN1184968C (zh) 2005-01-19
JP2014144982A (ja) 2014-08-14
PT1384478E (pt) 2011-05-12
HK1150756A1 (en) 2012-01-13
PT1117401E (pt) 2004-03-31
BRPI9914151B8 (enExample) 2021-05-25
PT2301541E (pt) 2014-10-29
HK1059572A1 (en) 2004-07-09
ES2207307T3 (es) 2004-05-16
AR020661A1 (es) 2002-05-22
WO2000018386A3 (en) 2000-06-08
ES2602956T3 (es) 2017-02-23
AU762827B2 (en) 2003-07-03
EP2301541A1 (en) 2011-03-30
HK1038691A1 (en) 2002-03-28
KR20010075138A (ko) 2001-08-09
CA2774207A1 (en) 2000-04-06
DE69912972D1 (de) 2003-12-24
CY1111404T1 (el) 2015-08-05
HK1038691B (en) 2004-04-23

Similar Documents

Publication Publication Date Title
DE69943287D1 (de) Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE494884T1 (de) Oxidative zusammensetzung zur behandlung von keratinfasern, die spezielle aminosilikone enthält
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE69612465D1 (de) Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
HUP9900927A3 (en) Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
NO991459D0 (no) Anvendelse av 1-hydroksy-2-pyridoner til behandling av hudinfeksjoner
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
NO994258L (no) Anvendelse av levobupivakain for behandling av ansiktsmigrene
DE3880953D1 (de) Chinolinderivate, verfahren zur herstellung davon und diese enthaltendes antibakterielles mittel.
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1384478

Country of ref document: EP